Back to News
Market Impact: 0.1
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
Source: globenewswire.com
Healthcare & BiotechProduct Launches
Dermavant’s former chief scientific officer led tapinarof’s development from mechanistic research through FDA approval and commercialization. The article identifies tapinarof as the first FDA-approved AhR agonist; it provides no financial results or current business update.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- All the news about the iPhone Duo
- The Tesla Roadster should go into production in 2028, but don't get your hopes up
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- Tesla Showcases Long-Awaited Roadster With Aerial Tricks
- After years of U.S. export bans, China plans its own: 40 AI, chip and solar technologies could be restricted
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Search Earnings Call Transcripts With AI
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI